Caribou Biosciences. Every tracked FinTwit mention of $CRBU, newest first. 15 mentions since the first on Nov 3, 2025. See the price chart.
November 2025 · 15 mentions
Nov 3
Jacob Plieth — @QueenBioInvest Yes, absolutely. So what's $CRBU's formula for ph3? 2+ or 4+? Age of donors? Anything else they might think up before then?↗
Nov 3
Jacob Plieth — @Sanctuary_Bio @adamfeuerstein This is just another sign that $CRBU floated way ahead of time. These kinds of scientific minutiae (HLA/no HLA, 2+/4+ alleles, young/old donors) shou…↗
Nov 3
Jacob Plieth — @adamfeuerstein How are the data better? 6mths ago $CRBU was claiming ORR 92% (post hoc). Now it's got ORR 82% (prospectively), and is tinkering with the HLA allele matching formul…↗
Nov 3
Adam Feuerstein ✡️ — @dadbodfamilyguy @JacobPlieth @ApexOnco No, $CRBU does not have the money needed to fund the ph3 trial of vispa-cel. I asked. How it raises the money, via a financing or partnershi…↗
Nov 3
Jacob Plieth — @adamfeuerstein I don't really see what's changed meaningfully since #ASCO25, apart from $CRBU being up 200%.↗
Nov 3
Adam Feuerstein ✡️ — @JacobPlieth @ApexOnco Isn't the more likely explanation for $CRBU flat today (after the initial bump) is the need to raise money to pay for the Ph3 trial?↗
Nov 3
Jacob Plieth — $CRBU +175% premarket, opened +30%, now flat. My take on the latest Antler data, via @ApexOnco -> https://t.co/GNYYkqjUsm $ALLO $GILD $ACLX $LEGN↗
Nov 3
Jacob Plieth — @DC_HC_Investor $CRBU https://t.co/unWL1IlJJp↗
Nov 3
Jacob Plieth — If I caught it correctly from $CRBU call: "optimised" vispa-cel (2+ HLA alleles, <30yo donors) requires 10 batches to be available to cover 98% of LBCL patients. The earlier vis…↗
Nov 3
Jacob Plieth — Because we all love cross-trial comparisons $CRBU https://t.co/5Tyzp8xZvj↗
Nov 3
Jacob Plieth — So off-the-shelf good, but need to match HLA takes away much of the advantage vs autologous. Plus $CRBU is still playing around to improve vispa-cel's profile. I'm not convinced th…↗
Nov 3
Jacob Plieth — Here we go: 82% ORR with $CRBU CBP-010 (now has the INN vispacabtagene regedleucel). That compares with 83% for $GILD Yescarta, and 87% for $BMY Breyanzi, on a cross-trial basis.↗
Nov 3
Adam Feuerstein ✡️ — Caribou Biosciences $CRBU said Monday that its off-the-shelf CAR-T therapy induced complete and durable remissions in patients with advanced B-cell lymphoma.
The study results, wh…↗
Nov 3
Adam Feuerstein ✡️ — $CRBU update on its off-the-shelf CAR-T programs at 7 am ET.↗
Nov 3
Jacob Plieth — Pretty meaty expectations ahead of $CRBU's long-awaited Antler update today. Reminder of how things stood at #ASCO25 https://t.co/rFvscaN6BH https://t.co/QlbdKLkrO1↗